These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25465598)

  • 1. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.
    Rodríguez AJ; Neeman T; Giles AG; Mastronardi CA; Paz Filho G
    Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):783-97. PubMed ID: 25465598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
    Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
    Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leptin-replacement therapy for lipodystrophy.
    Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
    N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
    Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
    Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P
    Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
    Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
    J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
    Mulligan K; Khatami H; Schwarz JM; Sakkas GK; DePaoli AM; Tai VW; Wen MJ; Lee GA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1137-44. PubMed ID: 19174500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
    J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.
    Kamran F; Rother KI; Cochran E; Safar Zadeh E; Gorden P; Brown RJ
    Horm Res Paediatr; 2012; 78(5-6):320-5. PubMed ID: 22965160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.
    Miyamoto L; Ebihara K; Kusakabe T; Aotani D; Yamamoto-Kataoka S; Sakai T; Aizawa-Abe M; Yamamoto Y; Fujikura J; Hayashi T; Hosoda K; Nakao K
    J Biol Chem; 2012 Nov; 287(48):40441-7. PubMed ID: 23024365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
    Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
    J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
    J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
    Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
    J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
    Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
    Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
    Gorden P; Park JY
    Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.
    Muniyappa R; Brown RJ; Mari A; Joseph J; Warren MA; Cochran EK; Skarulis MC; Gorden P
    Diabetes Care; 2014 Apr; 37(4):1101-7. PubMed ID: 24496806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.